Literature DB >> 29643318

Plasma Xanthine Oxidoreductase Activity as a Novel Biomarker of Metabolic Disorders in a General Population.

Masato Furuhashi1, Megumi Matsumoto1, Marenao Tanaka1, Norihito Moniwa1, Takayo Murase2, Takashi Nakamura2, Hirofumi Ohnishi1,3, Shigeyuki Saitoh1,4, Kazuaki Shimamoto5, Tetsuji Miura1.   

Abstract

BACKGROUND: Xanthine oxidoreductase (XOR) is an enzyme that catalyzes the formation of uric acid from hypoxanthine and xanthine, leading to an increase in superoxide and reactive oxygen species. Activation of XOR promotes oxidative stress-related tissue injury. We investigated the associations between metabolic parameters and plasma XOR activity measured by a sensitive and accurate assay using a combination of liquid chromatography and triple quadrupole mass spectrometry to detect [13C2,15N2]-uric acid using [13C2,15N2]-xanthine as a substrate.Methods and 
Results: A total of 627 Japanese subjects (M/F, 292/335) from the Tanno-Sobetsu Study, a population-based cohort, were recruited. Plasma XOR activity was significantly higher in males than in females, and habitual smoking was associated with elevation of activity. Plasma XOR activity was positively correlated with body mass index (BMI; r=0.323, P<0.001), waist circumference, blood pressure, and levels of liver enzymes including alanine transaminase (r=0.694, P<0.001), uric acid (r=0.249, P<0.001), triglycerides (r=0.312, P<0.001), hemoglobin A1c, fasting glucose, insulin and HOMA-R (r=0.238, P<0.001) as a marker of insulin resistance and was negatively correlated with high-density lipoprotein cholesterol level. On stepwise and multivariate regression analyses, BMI, smoking and levels of alanine transaminase, uric acid, triglycerides and HOMA-R were independent predictors of plasma XOR activity after adjustment for age and gender.
CONCLUSIONS: Plasma XOR activity is a novel biomarker of metabolic disorders in a general population.

Entities:  

Keywords:  Insulin resistance; Liver dysfunction; Obesity; Smoking; Uric acid

Mesh:

Substances:

Year:  2018        PMID: 29643318     DOI: 10.1253/circj.CJ-18-0082

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  24 in total

1.  Serum uric acid level is associated with an increase in systolic blood pressure over time in female subjects: Linear mixed-effects model analyses.

Authors:  Kazuma Mori; Masato Furuhashi; Marenao Tanaka; Yukimura Higashiura; Masayuki Koyama; Nagisa Hanawa; Hirofumi Ohnishi
Journal:  Hypertens Res       Date:  2021-11-30       Impact factor: 3.872

Review 2.  Hyperuricemia, Gout, and the Brain-an Update.

Authors:  Augustin Latourte; Julien Dumurgier; Claire Paquet; Pascal Richette
Journal:  Curr Rheumatol Rep       Date:  2021-12-30       Impact factor: 4.592

3.  Possible role of insulin resistance in activation of plasma xanthine oxidoreductase in health check-up examinees.

Authors:  Masafumi Kurajoh; Shinya Fukumoto; Seigo Akari; Takayo Murase; Takashi Nakamura; Kanae Takahashi; Hisako Yoshida; Shinya Nakatani; Akihiro Tsuda; Tomoaki Morioka; Katsuhito Mori; Yasuo Imanishi; Kazuto Hirata; Masanori Emoto
Journal:  Sci Rep       Date:  2022-06-18       Impact factor: 4.996

4.  High fibrosis-4 index predicts the new onset of ischaemic heart disease during a 10-year period in a general population.

Authors:  Yukimura Higashiura; Marenao Tanaka; Kazuma Mori; Takuma Mikami; Itaru Hosaka; Hirofumi Ohnishi; Nagisa Hanawa; Masato Furuhashi
Journal:  Eur Heart J Open       Date:  2022-04-16

Review 5.  Mini Review: Reappraisal of Uric Acid in Chronic Kidney Disease.

Authors:  Avi Goldberg; Fernando Garcia-Arroyo; Fumihiko Sasai; Bernardo Rodriguez-Iturbe; Laura Gabriela Sanchez-Lozada; Miguel A Lanaspa; Richard J Johnson
Journal:  Am J Nephrol       Date:  2021-10-21       Impact factor: 4.605

Review 6.  Impact of hyperuricemia on chronic kidney disease and atherosclerotic cardiovascular disease.

Authors:  Hitoshi Nishizawa; Norikazu Maeda; Iichiro Shimomura
Journal:  Hypertens Res       Date:  2022-01-19       Impact factor: 3.872

7.  Elevated Uric Acid Mediates the Effect of Obesity on Hypertension Development: A Causal Mediation Analysis in a Prospective Longitudinal Study.

Authors:  Conglin Hong; Qiu Zhang; Yan Chen; Ying Lu; Linan Chen; Yan He; Jing Li; Shengqi Ma; Jun Jiang; Xiaolong Zhang; Jianwei Hu; Yi Ding; Mingzhi Zhang; Hao Peng
Journal:  Clin Epidemiol       Date:  2022-04-11       Impact factor: 5.814

8.  Differential regulation of hypoxanthine and xanthine by obesity in a general population.

Authors:  Masato Furuhashi; Masayuki Koyama; Yukimura Higashiura; Takayo Murase; Takashi Nakamura; Megumi Matsumoto; Akiko Sakai; Hirofumi Ohnishi; Marenao Tanaka; Shigeyuki Saitoh; Norihito Moniwa; Kazuaki Shimamoto; Tetsuji Miura
Journal:  J Diabetes Investig       Date:  2020-02-09       Impact factor: 4.232

9.  Independent association of plasma xanthine oxidoreductase activity with hypertension in nondiabetic subjects not using medication.

Authors:  Masato Furuhashi; Yukimura Higashiura; Masayuki Koyama; Marenao Tanaka; Takayo Murase; Takashi Nakamura; Seigo Akari; Akiko Sakai; Kazuma Mori; Hirofumi Ohnishi; Shigeyuki Saitoh; Kazuaki Shimamoto; Tetsuji Miura
Journal:  Hypertens Res       Date:  2021-06-11       Impact factor: 3.872

10.  High level of fatty liver index predicts new onset of diabetes mellitus during a 10-year period in healthy subjects.

Authors:  Yukimura Higashiura; Masato Furuhashi; Marenao Tanaka; Satoko Takahashi; Masayuki Koyama; Hirofumi Ohnishi; Keita Numata; Takashi Hisasue; Nagisa Hanawa; Norihito Moniwa; Kazufumi Tsuchihashi; Tetsuji Miura
Journal:  Sci Rep       Date:  2021-06-18       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.